Nearly 20% of patients with type 2 diabetes do not benefit from exercise
the ONA take:
According to a new study published in the Journal of Clinical Endocrinology & Metabolism, one in five people with type 2 diabetes mellitus do not achieve any improvement in blood sugar control when they participate in a supervised exercise regimen.
For the study, researchers analyzed data from clinical studies that investigated the use of exercise regimens in patients with type 2 diabetes. They also looked at animal and genetic studies that did the same. Results showed that about 15 to 20% of patients with type 2 diabetes did not experience improvement in blood sugar control, insulin sensitivity, or muscle mitochondrial density.
The animal and genetic studies suggest that the resistance to exercise is genetic and can be passed from one generation to the next.
The U.S. Centers for Disease Control and Prevention estimates that about 40% of American will develop type 2 diabetes in their lifetime. Because obesity and lack of exercise are associated with the disease, exercise is often recommended to patients with diabetes to help manage the disease.
This study shows that while most people benefit from exercise, nearly 20% of patients with type 2 diabetes do not as a result of their DNA.
One in five people with type 2 diabetes mellitus do not achieve any improvement in blood sugar control.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|